Score Overview
Explore the 2021 public Archive ranking →
Where 4D Molecular Therapeutics Inc has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. FDMT does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 14.49 | — |
1 Year2025-09-29 | $ 8.35 | 73.53% |
5 Years2021-09-29 | $ 27.92 | -48.10% |
All Time2020-12-11 | $ 40.50 | -64.22% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | All Time2020-12-11 |
|---|---|---|---|---|
| Price | $ 14.49 | $ 8.35 | $ 27.92 | $ 40.50 |
| Return | — | 73.53% | -48.10% | -64.22% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 92M | -$ 179M | $ 361M |
| 2025 | $ 85M | -$ 140M | $ 402M |
| 2024 | -$ 160M | $ 424M | |
| 2023 | $ 20M | -$ 100M | $ 288M |
| 2022 | $ 3M | -$ 101M | $ 213M |
| 2021 | $ 18M | -$ 68M | $ 247M |
| IPO2020 | $ 13M | -$ 56M | $ 276M |
4D Molecular Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 13M to $ 85M and net income went from -$ 56M to -$ 140M. Revenue increased in 3 of those 5 years; net income in 2.
4D Molecular Therapeutics Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.
Membership
Explore FDMT with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
